Plain-English translation of NCT05573802 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new combination treatment for multiple myeloma — a cancer of blood cells — in people who have just been diagnosed and are not candidates for stem cell transplantation. The study combines belantamab mafodotin with three other medications (, , and ) to see if this combination is safe and how well it works. The research will help doctors find the best dose and treatment schedule for this medication combination.
Currently, people with newly diagnosed multiple myeloma who cannot have a stem cell transplant have limited treatment options. This trial exists to find out whether this new four-drug combination can be an effective option for these patients and to determine the safest way to give it.
You likely qualify if…
You likely don't qualify if…
You would take four medications in a carefully scheduled pattern over repeated cycles (each cycle is 28 days). The new medication is given by injection every 8 weeks, while the other three drugs are taken daily or on specific days of each cycle. You will have frequent clinic visits and blood tests during the first part of the study to monitor safety, and less frequent visits later. Your participation would continue for up to 3–4 years total, with the study aiming to enroll about 36 patients.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Greece